Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Case Study
  • Published:

False elevation of human chorionic gonadotropin in a patient with testicular cancer

Nature Reviews Urology volume 7, pages 230–233 (2010)Cite this article

Subjects

Abstract

Background. A 44-year-old, HIV-positive man presented with a painless swelling of his left testicle. He underwent left radical orchiectomy for a pathological stage T1 nonseminomatous germ cell tumor (NSGCT). A persistently elevated postoperative human chorionic gonadotropin (hCG) level resulted in the patient being diagnosed as having low-risk, stage 1S disseminated NSGCT. He was treated with four cycles of etoposide and cisplatin chemotherapy, but his hCG level had not returned to normal at the end of the treatment. Postchemotherapy CT showed no evidence of metastatic disease.

Investigations. Measurement of serum levels of tumor markers, including α-fetoprotein, hCG and lactate dehydrogenase, scrotal ultrasonography, HIV-1 reverse transcriptase polymerase chain reaction, CT of the thorax, abdomen and pelvis, assessment of kidney function, and measurement of follicle-stimulating hormone and luteinizing hormone levels.

Diagnosis. Falsely elevated serum hCG level caused by heterophile antibody interference in the hCG immunoassay.

Management. The patient's postchemotherapy serum samples were reanalyzed using a heterophile antibody blocking agent, the results of which showed no detectable hCG. No salvage therapy was required, and the patient remains in complete remission.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The patient's hCG levels postorchiectomy, demonstrating persistent elevation despite complete response to treatment.

References

  1. Esfandiari, N. & Goldberg, J. M. Heterophile antibody blocking agent to confirm false positive serum human chorionic gonadotropin assay. Obstet. Gynecol. 101, 1144–1146 (2003).

    PubMed  Google Scholar 

  2. Garnick, M. B. Spurious rise in human chorionic gonadotropin induced by marihuana in patients with testicular cancer. N. Engl. J. Med. 303, 1177 (1980).

    CAS  PubMed  Google Scholar 

  3. Buckner, C. L., Wilson, L. & Papadea, C. N. An unusual cause of elevated serum total βhCG. Ann. Clin. Lab. Sci. 37, 186–191 (2007).

    PubMed  Google Scholar 

  4. Willman, J. H. et al. Multiplex analysis of heterophil antibodies in patients with indeterminate HIV immunoassay results. Am. J. Clin. Pathol. 115, 764–769 (2001).

    Article  CAS  Google Scholar 

  5. Vidrih, J. A., Walensky, R. P., Sax, P. E. & Freedberg, K. A. Positive Epstein–Barr virus heterophile antibody tests in patients with primary human immunodeficiency virus infection. Am. J. Med. 111, 192–194 (2001).

    Article  CAS  Google Scholar 

  6. Kricka, L. J., Schmerfeld-Pruss, D., Senior, M., Goodman, D. B. & Kaladas, P. Interference by human anti-mouse antibody in two-site immunoassays. Clin. Chem. 36, 892–894 (1990).

    CAS  PubMed  Google Scholar 

  7. Azinovic, I. et al. Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies. Cancer Immunol. Immunother. 55, 1451–1458 (2006).

    Article  CAS  Google Scholar 

  8. Fritz, B. E., Hauke, R. J. & Stickle, D. F. New onset of heterophilic antibody interference in prostate-specific antigen measurement occurring during the period of post-prostatectomy prostate-specific antigen monitoring. Ann. Clin. Biochem. 46, 253–256 (2009).

    Article  CAS  Google Scholar 

  9. Morgan, B. R. & Tarter, T. H. Serum heterophile antibodies interfere with prostate specific antigen test and result in over treatment in a patient with prostate cancer. J. Urol. 166, 2311–2312 (2001).

    Article  CAS  Google Scholar 

  10. Park, S., Wians, F. H. Jr & Cadeddu, J. A. Spurious prostate-specific antigen (PSA) recurrence after radical prostatectomy: interference by human antimouse heterophile antibodies. Int. J. Urol. 14, 251–253 (2007).

    Article  CAS  Google Scholar 

  11. Davis, B. E., Herr, H. W., Fair, W. R. & Bosl, G. J. The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy. J. Urol. 152, 111–113 (1994).

    Article  CAS  Google Scholar 

  12. Culine, S., Theodore, C., Terrier-Lacombe, M. J. & Droz, J. P. Primary chemotherapy in patients with nonseminomatous germ cell tumors of the testis and biological disease only after orchiectomy. J. Urol. 155, 1296–1298 (1996).

    Article  CAS  Google Scholar 

  13. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology™ V.2.2009.

  14. Loehrer, P. J. Sr, Johnson, D., Elson, P., Einhorn, L. H. & Trump, D. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J. Clin. Oncol. 13, 470–476 (1995).

    Article  Google Scholar 

  15. de Wit, R. et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J. Clin. Oncol. 15, 1837–1843 (1997).

    Article  CAS  Google Scholar 

  16. Einhorn, L. H. et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J. Clin. Oncol. 7, 387–391 (1989).

    Article  CAS  Google Scholar 

  17. Culine, S. et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann. Oncol. 18, 917–924 (2007).

    Article  CAS  Google Scholar 

  18. Travis, L. B. et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J. Natl Cancer Inst. 97, 1354–1365 (2005).

    Article  Google Scholar 

  19. Kondagunta, G. V. et al. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J. Clin. Oncol. 23, 9290–9294 (2005).

    Article  CAS  Google Scholar 

  20. Motzer, R. J. et al. Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan–Kettering Cancer Center experience (1979–1989). Cancer 67, 1305–1310 (1991).

    Article  CAS  Google Scholar 

  21. Kondagunta, G. V. et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J. Clin. Oncol. 23, 6549–6555 (2005).

    Article  CAS  Google Scholar 

  22. Einhorn, L. H. et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N. Engl. J. Med. 357, 340–348 (2007).

    Article  CAS  Google Scholar 

  23. Motzer, R. J. et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J. Clin. Oncol. 25, 247–256 (2007).

    Article  CAS  Google Scholar 

  24. Saxman, S. B. et al. The management of patients with clinical stage I nonseminomatous testicular tumors and persistently elevated serologic markers. J. Urol. 155, 587–589 (1996).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Solid Tumor Oncology, Department of Medicine, Genitourinary Oncology Service, Memorial Sloan–Kettering Cancer Center, 1275 York Avenue, New York, 10065, NY, USA

    David J. Gallagher, Jamie Riches & Dean F. Bajorin

Authors
  1. David J. Gallagher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jamie Riches
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dean F. Bajorin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dean F. Bajorin.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gallagher, D., Riches, J. & Bajorin, D. False elevation of human chorionic gonadotropin in a patient with testicular cancer. Nat Rev Urol 7, 230–233 (2010). https://doi.org/10.1038/nrurol.2010.10

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2010.10

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer